SamRNA, the future of RNA medicines
* RCR is a novel in-vitro samRNA amplification technology optimized for industrial grade production of RNA/mRNA-based medicines as well as vaccines. Using recombinant viral replicase/RdRP enzymes, samRNA can be directly amplified from itself as a template without any hassle of DNA contamination. For preferential strand amplification in RCR, the desired sense (+) or antisense (-) strand samRNAs can be selectively amplified by using different combinations of strong and weak RdRP-binding sites in the designed samRNA construct. Most importantly, the amplified samRNA products are all in full-length conformation because both of its 5’- and 3’-end RdRP-binding sites must be intact in order to maintain the RCR activity, resulting in no or very limited RNA/mRNA degradation.
* SamRNA is the most advanced and advantageous RNA/mRNA medicine platform in the world. By changing the middle core RNA/mRNA sequence between the 5’- and 3’-end RdRP-binding sites of samRNA, we can easily design and manufacture a variety of RNA/mRNA medicines and/or vaccines useful for developing all kinds of treatments against many human diseases, such as viral infections, cancers, diabetes, spinal muscular atrophy (SMA), Alzheimer’s disease, and many more.